Colorectal cancer (CRC) is one of the most common cancers in both men and women in the United States, and comprises about 10% of new cancer cases. Colorectal cancer is an age-related epithelial cancer that often takes over twenty years to progress from initial benign adenoma (polyp) to invasive adenocarcinoma. The majority of colon cancers are characterized by genetic mutations in adenomatous polyposis coli (APC) or B-catenin, two key components of the Wnt signaling pathway. In the absence of Wnts, B-catenin is normally targeted for degradation by the GSK-3/Axin/APC complex. In the presence of Wnts, this degradation pathway is inhibited, B-catenin accumulates in the cytoplasm and nucleus and binds and transactivates Tcf/Lef proteins. Polyps arise when there is inappropriate activation of Wnt signaling, and B-catenin protein accumulates in the nucleus. We have recently developed a new mouse model of colon cancer where mice develop colon tumors that are consistent with those found in human FAP patients. As part of this proposal, we will further characterize this model using molecular tumor mariners. Additionally using mouse genetics, we will rigorously test via gain and loss of function studies, the role of Tcf4 on colon tumor formation in this mouse colon tumor model. Tcf4 is a member of the Tcf/Lef family of transcription factors that is essential for small intestinal cell proliferation and is expressed in human colon cancer cell lines and primary colon tumors. Taken together, results from these studies will provide important new insights into the role of Tcf4 during colon tumor formation, and may reveal novel downstream targets of Tcf4 function.
This research has broad relevance to the study of human colorectal cancer. Since it has been suggested that Tcf/Lef B-catenin protein complex is a viable target for colorectal cancer therapy, understanding the roles of Tcf4 during colon tumor formation in our mouse colon tumor model will provide valuable information for translational research and rational drug design.
|Delker, Don A; McGettigan, Brett M; Kanth, Priyanka et al. (2014) RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One 9:e88367|
|Samadder, N Jewel; Curtin, Karen; Tuohy, Thérèse M F et al. (2014) Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 146:950-60|
|Tuohy, Therese M F; Rowe, Kerry G; Mineau, Geraldine P et al. (2014) Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah. Cancer 120:35-42|
|Stafforini, Diana M; McIntyre, Thomas M (2013) Determination of phospholipase activity of PAF acetylhydrolase. Free Radic Biol Med 59:100-7|
|Hammoud, Saher Sue; Cairns, Bradley R; Jones, David A (2013) Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 25:177-83|
|Matsumiya, Tomoh; Xing, Fei; Ebina, Masayuki et al. (2013) Novel role for molecular transporter importin 9 in posttranscriptional regulation of IFN-ýý expression. J Immunol 191:1907-15|
|Sandoval, Imelda T; Manos, Elizabeth J; Van Wagoner, Ryan M et al. (2013) Juxtaposition of chemical and mutation-induced developmental defects in zebrafish reveal a copper-chelating activity for kalihinol F. Chem Biol 20:753-63|
|Teixeira-da-Cunha, Mariana G A; Gomes, Rachel N; Roehrs, Nathassia et al. (2013) Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration. PLoS One 8:e74567|
|Xu, Changxin; Reichert, Ethan C; Nakano, Tomoyuki et al. (2013) Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice. Cancer Res 73:2806-16|
|Jasperson, Kory W; Kanth, Priyanka; Kirchhoff, Anne C et al. (2013) Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis Colon Rectum 56:1211-6|
Showing the most recent 10 out of 82 publications